Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

NTNU genetic research shows best recipe to limit risk of lifestyle-related diseases

What should we eat? Answers abound in the international media, all of which rely on their interpretation of recent medical literature to come up with recommendations for the healthiest diet. But what if you could answer this question at a molecular level - what if you could find out how our genes respond to the foods we eat, and what this does to the cellular processes that make us healthy - or not? That's precisely what biologists at the Norwegian University of Science and Technology have done.

19 Sep 2011

Two newer Type 2 diabetes drugs could be linked to increased risk of pancreatic cancer

Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according to a new UCLA study.

19 Sep 2011

Multiple abstracts on QNEXA presented at 47th EASD

VIVUS, Inc. today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal. The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

17 Sep 2011

New diabetes drugs linked to increased risk of pancreatitis and pancreatic cancer

17 Sep 2011

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011

Linagliptin demonstrates durable reductions in blood glucose for T2D adults

Boehringer Ingelheim and Eli Lilly and Company today announced results of a 102 week Phase III study for linagliptin, which show meaningful and durable reductions in blood glucose for adults with type 2 diabetes.

16 Sep 2011

Researchers identify promising new therapies for ependymoma

Researchers have identified promising new therapies for ependymoma, a rare tumor with few treatment options. St. Jude Children's Research Hospital investigators led the effort, which used a new, faster drug development system that combines the latest drug screening technology with the first accurate animal model of the tumor.

16 Sep 2011

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes.

From Novo Nordisk 15 Sep 2011

Uterine stem cells could help treat diabetes

Controlling diabetes may someday involve mining stem cells from the lining of the uterus, Yale School of Medicine researchers report in a new study published in the journal Molecular Therapy.

15 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

Novo Nordisk announces free diabetes educational e-book series

Today, Novo Nordisk, a world leader in diabetes care, launched a free 5-volume diabetes educational e-book series, designed to help patients work with their health care team to better manage their diabetes. The e-book series is part of Cornerstones4Care™, an innovative patient support program that provides highly customizable diabetes information through the comprehensive interactive website www.Cornerstones4Care.com.

From Novo Nordisk 14 Sep 2011

A woman's pregnancy outcome can be an indicator of future health conditions

"A woman's pregnancy outcome can be an indicator of future health conditions," stated George R. Saade, M.D., president of the Society for Maternal-Fetal Medicine and professor of obstetrics and gynecology at The University of Texas Medical Branch in Galveston, Texas.

14 Sep 2011

Pure maple syrup may promote a healthy liver

New research conducted at the University of Tokyo suggests that pure maple syrup may promote a healthy liver.

14 Sep 2011

Survey highlights need for better diabetes treatment guidelines

A survey of federally funded diabetes prevention and control programs in 57 U.S. states and territories has highlighted the need for better diabetes treatment guidelines that are specifically adapted to different populations. Such guidelines do not currently exist.

14 Sep 2011

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011

High cholesterol and Alzheimer's disease

New research suggests that high cholesterol levels could boost the risk of Alzheimer's disease by creating more brain-clogging bits known as plaque. Researchers however didn't find any link between high cholesterol and tangles, which also clog the brain in those with Alzheimer's.

13 Sep 2011

A squirt of insulin up the nose for prevention of Alzheimer’s disease

Researchers have noted in a small pilot study that squirting insulin deep into the nose where it travels to the brain might hold early Alzheimer’s disease at bay. At present there are no effective ways to prevent or delay the progress of Alzheimer’s. More than 5.4 million Americans and 35 million people worldwide have Alzheimer's, the most common form of dementia.

13 Sep 2011

People with high cholesterol more likely to develop Alzheimer's disease

People with high cholesterol may have a higher risk of developing Alzheimer's disease, according to a study published in the September 13, 2011, issue of Neurology, the medical journal of the American Academy of Neurology.

13 Sep 2011

Cardiotrophin 1 has marked effect on fat and glucose metabolism

Scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have discovered that cardiotrophin 1, a protein synthesized by muscle cells and adipose tissue, has a marked effect on fat and glucose metabolism.

13 Sep 2011

Lantus initiation may help limit weight gain in type 2 diabetes patients

Sanofi announced today data that demonstrates that initiating Lantus® (insulin glargine [rDNA origin] injection) in type 2 diabetes patients leads to better glycemic control and comparable and modest weight gain versus a comparator group consisting of other insulins, oral antidiabetics and dietary changes.

12 Sep 2011